Skip to main content

Talphera, Inc.

corporate_fare Company Profile

Talphera, Inc.

TLPH·NASDAQ·Life Sciences·CIK 0001427925

TALPHERA, INC. is a specialty pharmaceutical company that develops and commercializes innovative therapies for use in medically supervised settings. The company's portfolio primarily focuses on its lead product candidate, Niyad (nafamostat mesylate), which is intended for use as a regional anticoagulant during continuous renal replacement therapy (CRRT). TALPHERA may also develop LTX-608, a nafamostat formulation designed for direct intravenous (IV) infusion. This formulation is being considered for one or more indications, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), acute pancreatitis, or as an anti-viral treatment. The company has two pre-filled syringe product candidates that are currently being evaluated for discontinuation. In January 2022, TALPHERA acquired Lowell Therapeutics, Inc. for approximately $32.5 million plus net cash acquired and certain other adjustments. This acquisition also included up to approximately $26.0 million of contingent consideration, payable in cash or stock at TALPHERA's option, upon achieving regulatory and sales-based milestones. Through this merger, TALPHERA acquired Niyad and LTX-608 (lyophilized vials of nafamostat for infusion into the extracorporeal circuit or direct IV infusion to the patient, respectively), which are considered in-process research and development (IPR&D) assets. Niyad, a lyophilized vial containing nafamostat for infusion, is intended as a regional anticoagulant for infusion into the extracorporeal circuit. It has received an investigational device exemption (IDE) and Breakthrough Device Designation from the United States Food and Drug Administration (FDA), and its registrational trial is ongoing with completion expected in 2026. LTX-608, also a lyophilized vial containing nafamostat for infusion, is being considered for IV infusion for DIC, ARDS, acute pancreatitis, or as an anti-viral treatment. An Investigational New Drug (IND) application for LTX-608 will be evaluated for submission following toxicology evaluation to enable a Phase 2 study.

Talphera, Inc. (NASDAQ:TLPH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for TLPH at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • CEO Angotti Vincent J. Buys $85K in Talphera Stock, Receives Significant Option Grant
  • CFO Buys $36.5K in Open Market Shares, Signaling Confidence

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$28K
Net Income
-$14.29M
Op. Cash Flow
-$11.36M
Operating Income
-$13.48M
Cash & Equivalents
$5.89M
Debt / Equity
0.00×
Net Margin
-510.36×
Shares Outstanding
49.33M sh
Source: 10-K · filed 2026-03-23 · accession 0001437749-26-009387
$0.8472 +7.90% today
52-week range · as of 2026-11-12 $0.6866 – $1.57
Market cap
$40.8M
Volume
357.3K (2.5× avg)
3-mo avg 141.3K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TLPH - Filings & News (Page 2)

TLPH
Feb 20, 2026, 8:28 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.7766
Real-time Price: $0.8472 info
Change: +$0.0706 (+9%) info
Market Cap: $40.797M info
TLPH
Feb 20, 2026, 8:23 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $0.7766
Real-time Price: $0.8472 info
Change: +$0.0706 (+9%) info
Market Cap: $40.797M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets